2nd Oncology Beyond the Obvious (OBTO) In-Person Conference | Prostate Cancer

Papers
a) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design from LANCET, 2022
b) Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial from JCO, 2023
Conference Directors: Dr. Amish Vora & Dr. Ullas Batra
Organizing Chairperson: Dr. Purvish Parikh
Scientific Co-chairpersons: Dr. Senthil Rajappa & Dr. Tarini Prasad Sahoo
Chairperson - Dr. Rangaraju Ranga Rao
Moderator - Dr Ghanashyam Biswas
Expert - Dr. Vineet Talwar